Influenza virus H5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans

J. E. Ledgerwood, Z. Hu, I. J. Gordon, G. Yamshchikov, M. E. Enama, S. Plummer, R. Bailer, M. B. Pearce, T. M. Tumpey, R. A. Koup, J. R. Mascola, G. J. Nabel, B. S. Graham

Research output: Contribution to journalArticle

Abstract

Avian influenza virus causes outbreaks in domestic and wild birds around the world, and sporadic human infections have been reported. A DNA vaccine encoding hemagglutinin (HA) protein from the A/Indonesia/5/05 (H5N1) strain was initially tested in two randomized phase I clinical studies. Vaccine Research Center study 304 (VRC 304) was a double-blinded study with 45 subjects randomized to placebo, 1 mg of vaccine, or 4 mg of vaccine treatment groups (n=15/group) by intramuscular (i.m.) Biojector injection. VRC 305 was an open-label study to evaluate route, with 44 subjects randomized to intradermal (i.d.) injections of 0.5 mg by needle/syringe or by Biojector or 1 mg delivered as two 0.5-mg Biojector injections in the same deltoid or as 0.5 mg in each deltoid (n=11/group). Injections were administered at weeks 0, 4, and 8 in both studies. Antibody responses to H5 were assessed by hemagglutination inhibition (HAI) assay, enzyme-linked immunosorbent assay (ELISA), and neutralization assay, and the H5 T cell responses were assessed by enzyme-linked immunospot and intracellular cytokine staining assays. There were no vaccine-related serious adverse events, and the vaccine was well tolerated in all groups. At 1 mg, i.d. vaccination compared to i.m. vaccination induced a greater frequency and magnitude of response by ELISA, but there were no significant differences in the frequency or magnitude of response between the i.d. and i.m. routes in the HAI or neutralization assays. T cell responses were more common in subjects who received the 1- or 4-mg dose i.m. These studies demonstrated that the DNA vaccine encoding H5 is safe and immunogenic and served to define the proper dose and route for further studies. The i.d. injection route did not offer a significant advantage over the i.m. route, and no difference was detected by delivery to one site versus splitting the dose between two sites for i.d. vaccine administration. The 4-mg dose (i.m) was further investigated in prime-boost regimens.

Original languageEnglish (US)
Pages (from-to)1792-1797
Number of pages6
JournalClinical and Vaccine Immunology
Volume19
Issue number11
DOIs
StatePublished - Nov 2012
Externally publishedYes

Fingerprint

Orthomyxoviridae
Viruses
Assays
Vaccination
Vaccines
DNA
Intradermal Injections
Immunosorbents
DNA Vaccines
T-cells
Hemagglutination
Enzymes
Enzyme-Linked Immunosorbent Assay
T-Lymphocytes
Syringes
Injections
Influenza in Birds
Indonesia
Intramuscular Injections
Staphylococcal Protein A

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

Ledgerwood, J. E., Hu, Z., Gordon, I. J., Yamshchikov, G., Enama, M. E., Plummer, S., ... Graham, B. S. (2012). Influenza virus H5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clinical and Vaccine Immunology, 19(11), 1792-1797. https://doi.org/10.1128/CVI.05663-11

Influenza virus H5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. / Ledgerwood, J. E.; Hu, Z.; Gordon, I. J.; Yamshchikov, G.; Enama, M. E.; Plummer, S.; Bailer, R.; Pearce, M. B.; Tumpey, T. M.; Koup, R. A.; Mascola, J. R.; Nabel, G. J.; Graham, B. S.

In: Clinical and Vaccine Immunology, Vol. 19, No. 11, 11.2012, p. 1792-1797.

Research output: Contribution to journalArticle

Ledgerwood, JE, Hu, Z, Gordon, IJ, Yamshchikov, G, Enama, ME, Plummer, S, Bailer, R, Pearce, MB, Tumpey, TM, Koup, RA, Mascola, JR, Nabel, GJ & Graham, BS 2012, 'Influenza virus H5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans', Clinical and Vaccine Immunology, vol. 19, no. 11, pp. 1792-1797. https://doi.org/10.1128/CVI.05663-11
Ledgerwood, J. E. ; Hu, Z. ; Gordon, I. J. ; Yamshchikov, G. ; Enama, M. E. ; Plummer, S. ; Bailer, R. ; Pearce, M. B. ; Tumpey, T. M. ; Koup, R. A. ; Mascola, J. R. ; Nabel, G. J. ; Graham, B. S. / Influenza virus H5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. In: Clinical and Vaccine Immunology. 2012 ; Vol. 19, No. 11. pp. 1792-1797.
@article{81de3b5554b0443cba73e41f9cec28a2,
title = "Influenza virus H5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans",
abstract = "Avian influenza virus causes outbreaks in domestic and wild birds around the world, and sporadic human infections have been reported. A DNA vaccine encoding hemagglutinin (HA) protein from the A/Indonesia/5/05 (H5N1) strain was initially tested in two randomized phase I clinical studies. Vaccine Research Center study 304 (VRC 304) was a double-blinded study with 45 subjects randomized to placebo, 1 mg of vaccine, or 4 mg of vaccine treatment groups (n=15/group) by intramuscular (i.m.) Biojector injection. VRC 305 was an open-label study to evaluate route, with 44 subjects randomized to intradermal (i.d.) injections of 0.5 mg by needle/syringe or by Biojector or 1 mg delivered as two 0.5-mg Biojector injections in the same deltoid or as 0.5 mg in each deltoid (n=11/group). Injections were administered at weeks 0, 4, and 8 in both studies. Antibody responses to H5 were assessed by hemagglutination inhibition (HAI) assay, enzyme-linked immunosorbent assay (ELISA), and neutralization assay, and the H5 T cell responses were assessed by enzyme-linked immunospot and intracellular cytokine staining assays. There were no vaccine-related serious adverse events, and the vaccine was well tolerated in all groups. At 1 mg, i.d. vaccination compared to i.m. vaccination induced a greater frequency and magnitude of response by ELISA, but there were no significant differences in the frequency or magnitude of response between the i.d. and i.m. routes in the HAI or neutralization assays. T cell responses were more common in subjects who received the 1- or 4-mg dose i.m. These studies demonstrated that the DNA vaccine encoding H5 is safe and immunogenic and served to define the proper dose and route for further studies. The i.d. injection route did not offer a significant advantage over the i.m. route, and no difference was detected by delivery to one site versus splitting the dose between two sites for i.d. vaccine administration. The 4-mg dose (i.m) was further investigated in prime-boost regimens.",
author = "Ledgerwood, {J. E.} and Z. Hu and Gordon, {I. J.} and G. Yamshchikov and Enama, {M. E.} and S. Plummer and R. Bailer and Pearce, {M. B.} and Tumpey, {T. M.} and Koup, {R. A.} and Mascola, {J. R.} and Nabel, {G. J.} and Graham, {B. S.}",
year = "2012",
month = "11",
doi = "10.1128/CVI.05663-11",
language = "English (US)",
volume = "19",
pages = "1792--1797",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Influenza virus H5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans

AU - Ledgerwood, J. E.

AU - Hu, Z.

AU - Gordon, I. J.

AU - Yamshchikov, G.

AU - Enama, M. E.

AU - Plummer, S.

AU - Bailer, R.

AU - Pearce, M. B.

AU - Tumpey, T. M.

AU - Koup, R. A.

AU - Mascola, J. R.

AU - Nabel, G. J.

AU - Graham, B. S.

PY - 2012/11

Y1 - 2012/11

N2 - Avian influenza virus causes outbreaks in domestic and wild birds around the world, and sporadic human infections have been reported. A DNA vaccine encoding hemagglutinin (HA) protein from the A/Indonesia/5/05 (H5N1) strain was initially tested in two randomized phase I clinical studies. Vaccine Research Center study 304 (VRC 304) was a double-blinded study with 45 subjects randomized to placebo, 1 mg of vaccine, or 4 mg of vaccine treatment groups (n=15/group) by intramuscular (i.m.) Biojector injection. VRC 305 was an open-label study to evaluate route, with 44 subjects randomized to intradermal (i.d.) injections of 0.5 mg by needle/syringe or by Biojector or 1 mg delivered as two 0.5-mg Biojector injections in the same deltoid or as 0.5 mg in each deltoid (n=11/group). Injections were administered at weeks 0, 4, and 8 in both studies. Antibody responses to H5 were assessed by hemagglutination inhibition (HAI) assay, enzyme-linked immunosorbent assay (ELISA), and neutralization assay, and the H5 T cell responses were assessed by enzyme-linked immunospot and intracellular cytokine staining assays. There were no vaccine-related serious adverse events, and the vaccine was well tolerated in all groups. At 1 mg, i.d. vaccination compared to i.m. vaccination induced a greater frequency and magnitude of response by ELISA, but there were no significant differences in the frequency or magnitude of response between the i.d. and i.m. routes in the HAI or neutralization assays. T cell responses were more common in subjects who received the 1- or 4-mg dose i.m. These studies demonstrated that the DNA vaccine encoding H5 is safe and immunogenic and served to define the proper dose and route for further studies. The i.d. injection route did not offer a significant advantage over the i.m. route, and no difference was detected by delivery to one site versus splitting the dose between two sites for i.d. vaccine administration. The 4-mg dose (i.m) was further investigated in prime-boost regimens.

AB - Avian influenza virus causes outbreaks in domestic and wild birds around the world, and sporadic human infections have been reported. A DNA vaccine encoding hemagglutinin (HA) protein from the A/Indonesia/5/05 (H5N1) strain was initially tested in two randomized phase I clinical studies. Vaccine Research Center study 304 (VRC 304) was a double-blinded study with 45 subjects randomized to placebo, 1 mg of vaccine, or 4 mg of vaccine treatment groups (n=15/group) by intramuscular (i.m.) Biojector injection. VRC 305 was an open-label study to evaluate route, with 44 subjects randomized to intradermal (i.d.) injections of 0.5 mg by needle/syringe or by Biojector or 1 mg delivered as two 0.5-mg Biojector injections in the same deltoid or as 0.5 mg in each deltoid (n=11/group). Injections were administered at weeks 0, 4, and 8 in both studies. Antibody responses to H5 were assessed by hemagglutination inhibition (HAI) assay, enzyme-linked immunosorbent assay (ELISA), and neutralization assay, and the H5 T cell responses were assessed by enzyme-linked immunospot and intracellular cytokine staining assays. There were no vaccine-related serious adverse events, and the vaccine was well tolerated in all groups. At 1 mg, i.d. vaccination compared to i.m. vaccination induced a greater frequency and magnitude of response by ELISA, but there were no significant differences in the frequency or magnitude of response between the i.d. and i.m. routes in the HAI or neutralization assays. T cell responses were more common in subjects who received the 1- or 4-mg dose i.m. These studies demonstrated that the DNA vaccine encoding H5 is safe and immunogenic and served to define the proper dose and route for further studies. The i.d. injection route did not offer a significant advantage over the i.m. route, and no difference was detected by delivery to one site versus splitting the dose between two sites for i.d. vaccine administration. The 4-mg dose (i.m) was further investigated in prime-boost regimens.

UR - http://www.scopus.com/inward/record.url?scp=84868217771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868217771&partnerID=8YFLogxK

U2 - 10.1128/CVI.05663-11

DO - 10.1128/CVI.05663-11

M3 - Article

C2 - 22956656

AN - SCOPUS:84868217771

VL - 19

SP - 1792

EP - 1797

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 11

ER -